Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. more
Time Frame | IMCR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.06% | -0.94% | -2.6% |
1-Month Return | -14.18% | -5.08% | -1.08% |
3-Month Return | -8.64% | -10.62% | 3.45% |
6-Month Return | -21.46% | -6.18% | 8.57% |
1-Year Return | -58.64% | 1.98% | 24.3% |
3-Year Return | -20.6% | -0.93% | 25.58% |
5-Year Return | -34.86% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 25.67M | 30.11M | 26.52M | 143.74M | 249.43M | [{"date":"2019-12-31","value":10.29,"profit":true},{"date":"2020-12-31","value":12.07,"profit":true},{"date":"2021-12-31","value":10.63,"profit":true},{"date":"2022-12-31","value":57.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 99.99M | 74.81M | 73.23M | 454.00K | 1.04M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":74.82,"profit":true},{"date":"2021-12-31","value":73.23,"profit":true},{"date":"2022-12-31","value":0.45,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true}] |
Gross Profit | (74.32M) | (44.70M) | (46.71M) | 143.28M | 248.39M | [{"date":"2019-12-31","value":-29.92,"profit":false},{"date":"2020-12-31","value":-17.99,"profit":false},{"date":"2021-12-31","value":-18.8,"profit":false},{"date":"2022-12-31","value":57.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (289.54%) | (148.42%) | (176.12%) | 99.68% | 99.58% | [{"date":"2019-12-31","value":-290.46,"profit":false},{"date":"2020-12-31","value":-148.89,"profit":false},{"date":"2021-12-31","value":-176.67,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.9,"profit":true}] |
Operating Expenses | 144.17M | 119.40M | 161.68M | 182.89M | 308.04M | [{"date":"2019-12-31","value":46.8,"profit":true},{"date":"2020-12-31","value":38.76,"profit":true},{"date":"2021-12-31","value":52.49,"profit":true},{"date":"2022-12-31","value":59.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (118.32M) | (86.19M) | (135.16M) | (39.61M) | (59.65M) | [{"date":"2019-12-31","value":-11832000000,"profit":false},{"date":"2020-12-31","value":-8619300000,"profit":false},{"date":"2021-12-31","value":-13516200000,"profit":false},{"date":"2022-12-31","value":-3960700000,"profit":false},{"date":"2023-12-31","value":-5964900000,"profit":false}] |
Total Non-Operating Income/Expense | (10.27M) | (3.57M) | 27.89M | 1.25M | 3.24M | [{"date":"2019-12-31","value":-36.83,"profit":false},{"date":"2020-12-31","value":-12.8,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.48,"profit":true},{"date":"2023-12-31","value":11.63,"profit":true}] |
Pre-Tax Income | (126.19M) | (87.36M) | (140.93M) | (44.15M) | (60.89M) | [{"date":"2019-12-31","value":-12618900000,"profit":false},{"date":"2020-12-31","value":-8736000000,"profit":false},{"date":"2021-12-31","value":-14092800000,"profit":false},{"date":"2022-12-31","value":-4414500000,"profit":false},{"date":"2023-12-31","value":-6089000000,"profit":false}] |
Income Taxes | (22.26M) | (13.27M) | (9.40M) | (2.92M) | (5.60M) | [{"date":"2019-12-31","value":-2225800000,"profit":false},{"date":"2020-12-31","value":-1326700000,"profit":false},{"date":"2021-12-31","value":-940500000,"profit":false},{"date":"2022-12-31","value":-292100000,"profit":false},{"date":"2023-12-31","value":-560300000,"profit":false}] |
Income After Taxes | (103.93M) | (74.09M) | (131.52M) | (41.22M) | (55.29M) | [{"date":"2019-12-31","value":-10393100000,"profit":false},{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5528700000,"profit":false}] |
Income From Continuous Operations | (103.93M) | (74.09M) | (131.52M) | (41.22M) | (54.07M) | [{"date":"2019-12-31","value":-10393100000,"profit":false},{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5407300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (103.93M) | (74.09M) | (131.52M) | (41.22M) | (55.29M) | [{"date":"2019-12-31","value":-10393100000,"profit":false},{"date":"2020-12-31","value":-7409300000,"profit":false},{"date":"2021-12-31","value":-13152300000,"profit":false},{"date":"2022-12-31","value":-4122400000,"profit":false},{"date":"2023-12-31","value":-5528700000,"profit":false}] |
EPS (Diluted) | (13.69) | (0.83) | (93.89) | (93.00) | (63.59) | [{"date":"2019-12-31","value":-1369.08,"profit":false},{"date":"2020-12-31","value":-82.84,"profit":false},{"date":"2021-12-31","value":-9389,"profit":false},{"date":"2022-12-31","value":-9300,"profit":false},{"date":"2023-12-31","value":-6359,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMCR | |
---|---|
Cash Ratio | 3.39 |
Current Ratio | 3.78 |
Quick Ratio | 3.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMCR | |
---|---|
ROA (LTM) | -5.22% |
ROE (LTM) | -12.83% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMCR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.65 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMCR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.78 |
P/B | 3.75 |
Price/FCF | 70 |
EV/R | 3.36 |
EV/Ebitda | NM |
Immunocore Holdings Ltd (IMCR) share price today is $28.14
Yes, Indians can buy shares of Immunocore Holdings Ltd (IMCR) on Vested. To buy Immunocore Holdings Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immunocore Holdings Ltd (IMCR) via the Vested app. You can start investing in Immunocore Holdings Ltd (IMCR) with a minimum investment of $1.
You can invest in shares of Immunocore Holdings Ltd (IMCR) via Vested in three simple steps:
The 52-week high price of Immunocore Holdings Ltd (IMCR) is $76.98. The 52-week low price of Immunocore Holdings Ltd (IMCR) is $27.69.
The price-to-earnings (P/E) ratio of Immunocore Holdings Ltd (IMCR) is
The price-to-book (P/B) ratio of Immunocore Holdings Ltd (IMCR) is 3.75
The dividend yield of Immunocore Holdings Ltd (IMCR) is 0.00%
The market capitalization of Immunocore Holdings Ltd (IMCR) is $1.42B
The stock symbol (or ticker) of Immunocore Holdings Ltd is IMCR